These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33723319)

  • 21. ALPL regulates the aggressive potential of high grade serous ovarian cancer cells via a non-canonical WNT pathway.
    Luo M; Zhou L; Zhan SJ; Cheng LJ; Li RN; Wang H; Liu B; Linghu H
    Biochem Biophys Res Commun; 2019 May; 513(2):528-533. PubMed ID: 30979497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 37-kDa laminin receptor precursor mediates GnRH-II-induced MMP-2 expression and invasiveness in ovarian cancer cells.
    Poon SL; Klausen C; Hammond GL; Leung PC
    Mol Endocrinol; 2011 Feb; 25(2):327-38. PubMed ID: 21193558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RSPO2 suppresses colorectal cancer metastasis by counteracting the Wnt5a/Fzd7-driven noncanonical Wnt pathway.
    Dong X; Liao W; Zhang L; Tu X; Hu J; Chen T; Dai X; Xiong Y; Liang W; Ding C; Liu R; Dai J; Wang O; Lu L; Lu X
    Cancer Lett; 2017 Aug; 402():153-165. PubMed ID: 28600110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pectasol-C Modified Citrus Pectin targets Galectin-3-induced STAT3 activation and synergize paclitaxel cytotoxic effect on ovarian cancer spheroids.
    Hossein G; Halvaei S; Heidarian Y; Dehghani-Ghobadi Z; Hassani M; Hosseini H; Naderi N; Sheikh Hassani S
    Cancer Med; 2019 Aug; 8(9):4315-4329. PubMed ID: 31197964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Wnt5A exerts immunomodulatory activity in the human ovarian cancer cell line SKOV-3.
    Arabzadeh S; Hossein G; Zarnani AH
    Cell Biol Int; 2016 Feb; 40(2):177-87. PubMed ID: 26462870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Laminin gamma2 mediates Wnt5a-induced invasion of gastric cancer cells.
    Yamamoto H; Kitadai Y; Yamamoto H; Oue N; Ohdan H; Yasui W; Kikuchi A
    Gastroenterology; 2009 Jul; 137(1):242-52, 252.e1-6. PubMed ID: 19582886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion.
    Jenei V; Sherwood V; Howlin J; Linnskog R; Säfholm A; Axelsson L; Andersson T
    Proc Natl Acad Sci U S A; 2009 Nov; 106(46):19473-8. PubMed ID: 19901340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3.
    Gourley C; Paige AJ; Taylor KJ; Ward C; Kuske B; Zhang J; Sun M; Janczar S; Harrison DJ; Muir M; Smyth JF; Gabra H
    Cancer Res; 2009 Jun; 69(11):4835-42. PubMed ID: 19458077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. WNT5A: a motility-promoting factor in Hodgkin lymphoma.
    Linke F; Zaunig S; Nietert MM; von Bonin F; Lutz S; Dullin C; Janovská P; Beissbarth T; Alves F; Klapper W; Bryja V; Pukrop T; Trümper L; Wilting J; Kube D
    Oncogene; 2017 Jan; 36(1):13-23. PubMed ID: 27270428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibronectin Regulates the Dynamic Formation of Ovarian Cancer Multicellular Aggregates and the Expression of Integrin Receptors.
    Gong L; Zheng Y; Liu S; Peng Z
    Asian Pac J Cancer Prev; 2018 Sep; 19(9):2493-2498. PubMed ID: 30256042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Migration and invasion of oral squamous carcinoma cells is promoted by WNT5A, a regulator of cancer progression.
    Prgomet Z; Axelsson L; Lindberg P; Andersson T
    J Oral Pathol Med; 2015 Nov; 44(10):776-84. PubMed ID: 25459554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Wnt5a promotes vasculogenic mimicry and epithelial-mesenchymal transition via protein kinase Cα in epithelial ovarian cancer.
    Qi H; Sun B; Zhao X; Du J; Gu Q; Liu Y; Cheng R; Dong X
    Oncol Rep; 2014 Aug; 32(2):771-9. PubMed ID: 24898696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. WNT signaling inducing activity in ascites predicts poor outcome in ovarian cancer.
    Kotrbová A; Ovesná P; Gybel' T; Radaszkiewicz T; Bednaříková M; Hausnerová J; Jandáková E; Minář L; Crha I; Weinberger V; Záveský L; Bryja V; Pospíchalová V
    Theranostics; 2020; 10(2):537-552. PubMed ID: 31903136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions.
    Elloul S; Vaksman O; Stavnes HT; Trope CG; Davidson B; Reich R
    Clin Exp Metastasis; 2010 Mar; 27(3):161-72. PubMed ID: 20213325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation.
    Ricciardelli C; Lokman NA; Cheruvu S; Tan IA; Ween MP; Pyragius CE; Ruszkiewicz A; Hoffmann P; Oehler MK
    Clin Exp Metastasis; 2015 Jun; 32(5):441-55. PubMed ID: 25895698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells.
    Zhang R; Shi H; Chen Z; Wu Q; Ren F; Huang H
    J Exp Clin Cancer Res; 2011 Sep; 30(1):83. PubMed ID: 21923915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The mannose receptor LY75 (DEC205/CD205) modulates cellular phenotype and metastatic potential of ovarian cancer cells.
    Faddaoui A; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Gobeil S; Morin C; Macdonald E; Vanderhyden B; Bachvarov D
    Oncotarget; 2016 Mar; 7(12):14125-42. PubMed ID: 26871602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells.
    Alper O ; Bergmann-Leitner ES; Bennett TA; Hacker NF; Stromberg K; Stetler-Stevenson WG
    J Natl Cancer Inst; 2001 Sep; 93(18):1375-84. PubMed ID: 11562388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling.
    Enomoto M; Hayakawa S; Itsukushima S; Ren DY; Matsuo M; Tamada K; Oneyama C; Okada M; Takumi T; Nishita M; Minami Y
    Oncogene; 2009 Sep; 28(36):3197-208. PubMed ID: 19561643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ectopic repression of receptor tyrosine kinase-like orphan receptor 2 inhibits malignant transformation of ovarian cancer cells by reversing epithelial-mesenchymal transition.
    Xu Y; Ma YH; Pang YX; Zhao Z; Lu JJ; Mao HL; Liu PS
    Tumour Biol; 2017 May; 39(5):1010428317701627. PubMed ID: 28475014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.